Track papers across labs, topics, and trends.
Search papers, labs, and topics across Lattice.
1
0
0
39
With longer follow-up, most participants receiving talquetamab continued to experience improvement in their multiple myeloma, and although side effects were common, very few participants stopped talquetamab treatment because of side effects.